ArticleJournal of the Endocrine Society2019
Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma.
Article in Journal of the Endocrine Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women.Clinical endocrinology · 2025Guideline
- Adrenal Medullary Hyperplasia: A Systematic Review and Meta-analysis.The Journal of clinical endocrinology and metabolism · 2023Pooled it
- Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered Takotsubo syndrome: A systematic review and meta-analysis of 156 published cases.Clinical cardiology · 2020Pooled it
- Robot-Assisted Laparoscopic Partial Adrenalectomy Utilizing Intraoperative Indocyanine Green Near-Infrared Fluorescence Imaging for Pheochromocytoma: A Case Report.IJU case reports · 2026Article
- Differences in management and outcomes between pheochromocytomas and sympathetic paragangliomas.Frontiers in endocrinology · 2026Article
- Coexistence of primary aldosteronism and micro-pheochromocytoma: a case report with pathological analysis and literature review.Frontiers in medicine · 2026Article
- Differences in Clinical Presentation Between Pheochromocytomas and Paragangliomas.Clinical endocrinology · 2025Article
- Sex differences in management and outcomes in pheochromocytomas and paragangliomas.Frontiers in endocrinology · 2025Article
- A Cortisol-Secreting Adrenal Adenoma Combined With a Micro-Pheochromocytoma: Case Report and Literature Review.Clinical medicine insights. Endocrinology and diabetes · 2023Article
- Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.Endocrine pathology · 2022Review
- Review
- Clinical identification of expressed proteins in adrenal medullary hyperplasia detected with hypertension.Frontiers in endocrinology · 2022Article
- Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.Endocrine pathology · 2021Review
- Case Report: Three Rare Cases of Ectopic ACTH Syndrome Caused by Adrenal Medullary Hyperplasia.Frontiers in endocrinology · 2021Article
- Adrenal medullary hyperplasia mimicking pheochromocytoma.BMJ case reports · 2020Article
- Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextInformation about adrenal medullary hyperplasia (AMH) is scarce.
objectiveTo study a large cohort of AMHs. DESIGN SETTING AND
participantsNineteen AMH cases were compared with 95 pheochromocytomas (PCCs) without AMH. AMH without (n = 7) and with PCC (n = 12) were analyzed separately.
resultsOf 936 adrenalectomies, 2.1% had AMH. Mean age was 47.2 ± 15.1 years. Only two (11%) AMHs had no concurrent PCC or adrenocortical adenoma. In AMHs, a genetic syndrome was present in 58% vs 4% in PCCs (
conclusionA total of 2.1% of all adrenalectomies displayed AMH. AMH seemed to be a PCC precursor. The symptoms and signs were milder than PCCs. AMHs were mainly found due to screening. Outcomes seemed favorable, but new PCCs developed in many during follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.